- Home
- NTLA vs AIO Comparison
NTLA vs AIO Comparison
Compare NTLA & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- AIO
- Stock Information
- Founded
- NTLA 2014
- AIO 2019
- Country
- NTLA United States
- AIO United States
- Employees
- NTLA N/A
- AIO N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AIO Finance/Investors Services
- Sector
- NTLA Health Care
- AIO Finance
- Exchange
- NTLA Nasdaq
- AIO Nasdaq
- Market Cap
- NTLA 931.3M
- AIO 808.3M
- IPO Year
- NTLA 2016
- AIO N/A
- Fundamental
- Price
- NTLA $9.02
- AIO $23.39
- Analyst Decision
- NTLA Buy
- AIO
- Analyst Count
- NTLA 22
- AIO 0
- Target Price
- NTLA $19.83
- AIO N/A
- AVG Volume (30 Days)
- NTLA 8.3M
- AIO 141.5K
- Earning Date
- NTLA 11-06-2025
- AIO 01-01-0001
- Dividend Yield
- NTLA N/A
- AIO 9.05%
- EPS Growth
- NTLA N/A
- AIO N/A
- EPS
- NTLA N/A
- AIO N/A
- Revenue
- NTLA $57,528,000.00
- AIO N/A
- Revenue This Year
- NTLA $8.51
- AIO N/A
- Revenue Next Year
- NTLA N/A
- AIO N/A
- P/E Ratio
- NTLA N/A
- AIO N/A
- Revenue Growth
- NTLA 33.52
- AIO N/A
- 52 Week Low
- NTLA $5.90
- AIO $15.09
- 52 Week High
- NTLA $28.25
- AIO $20.25
- Technical
- Relative Strength Index (RSI)
- NTLA 35.68
- AIO 52.41
- Support Level
- NTLA $8.96
- AIO $21.46
- Resistance Level
- NTLA $8.88
- AIO $23.15
- Average True Range (ATR)
- NTLA 0.63
- AIO 0.58
- MACD
- NTLA 0.26
- AIO 0.03
- Stochastic Oscillator
- NTLA 38.33
- AIO 67.98
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.